Highest-materiality recent filing
Genelux enters $100M at-the-market equity offering agreement with TD Cowen
Sales Agreement with TD Cowen allows offering of common stock up to $100M aggregate.
Genelux furnishes updated corporate presentation; no specifics disclosed
Presentation dated February 2026 includes business and strategic updates.
Genelux prices $20M public offering of 6.7M shares at $3.00
Priced underwritten public offering of 6,666,667 shares at $3.00 each.
Genelux reports 33% ORR in SCLC and 60% DCR in NSCLC with systemic Olvi-Vec
SCLC Phase 1b/2: 33% ORR (3/9 PRs), 67% DCR; highest dose cohort 67% ORR (2/3) with tumor shrinkage ~55% and ~85%.
Genelux appoints Jason Litten as CMO after Paul Scigalla resigns
Paul Scigalla, M.D., resigned as CMO effective December 30, 2025.
Genelux reprices employee stock options to $3.33 from up to $22.40; covers 2.7M shares
Exercise price reduced to $3.33 for eligible options with prior range $6.00–$22.40 per share.
Genelux reports preliminary cash ~$30.9M; positive Olvi-Vec SCLC data and FDA guidance for PRROC
Preliminary cash, cash equivalents, and short-term investments as of Dec 31, 2024: ~$30.9M (unaudited).
Genelux prices $10.5M underwritten offering of 3M shares at $3.50/share
Gross proceeds of $10.5M from 3,000,000 shares at $3.50 per share; closing expected March 26, 2025.
Genelux CFO Lourie Zak resigns; Matt Pulisic appointed CFO with $410k salary, 275k option
Lourie Zak resigned as CFO effective Jan 29, 2025; separation includes $180k cash payment (6 months salary) and advisory role through Aug 29, 2025.
Genelux made available a corporate presentation for use in investor and analyst meetings.
Genelux VP of Quality Caroline Jewett resigns effective Oct 18, 2024
Caroline Jewett resigned as VP, Head of Quality, effective October 18, 2024.
Genelux holds 2024 annual meeting; elects two Class II directors
Elected Mary Mirabelli as Class II director with 13,349,192 votes for, 1,386,089 withheld, and 7,740,438 broker non-votes.
Genelux posts corporate presentation on August 1, 2024; no specific new data disclosed in filing
Furnished corporate presentation as Exhibit 99.1 under Regulation FD.
Genelux receives ~$2.35M net from partial overallotment exercise by underwriters
Underwriters exercised option to purchase 625,000 shares and warrants at $4.00 per unit.
Genelux prices $27.5M offering of 6.875M shares and warrants at $4.00
Gross proceeds ~$27.5M; net ~$25.4M from 6,875,000 shares and 6,875,000 warrants at combined $4.00/unit.
On February 3, 2025, the Company announced the appointment of Matt Pulisic as the Company’s Chief Financial Officer, effective as of January 30, 2025 (the “ Effective Date ”).
On January 29, 2025 (the “ Separation Date ”), Lourie Zak resigned as Chief Financial Officer of Genelux Corporation (the “ Company ”), effective immediately.
On September 23, 2024, Caroline Jewett notified Genelux Corporation (the “Company”) of her resignation as Vice President, Head of Quality of the Company, effective as of October 18, 2024.
Max materiality 0.85 · Median 0.60 · Most common event other_material